; (C) a description of progress to expand diagnosis, prevention, and treatment for all forms of tuberculosis, including in pregnant women, children, and other high-risk groups who are vulnerable or in vulnerable situations, such as migrants, prisoners, miners, and others exposed to silica, and people living with HIV/AIDS, disaggregated by sex; (D) the rate of successful completion of tuberculosis treatment for adults and children, disaggregated by sex, and the number of patients receiving support for treatment completion; (E) the number of people, disaggregated by sex, receiving treatment for MDR–TB, the proportion of those treated with the latest regimens endorsed by the World Health Organization, any factors impeding scale up of such treatment, and a description of progress to expand community-based MDR–TB care; (F) a description of tuberculosis commodity procurement challenges, including shortages, stockouts, or failed tenders for tuberculosis drugs or other commodities; (G) the proportion of health facilities with specimen referral linkages to GeneXpert testing sites, and to reference labs for second line drug resistance testing, and a description of the turnaround time for test results; (H) the number of people trained by the United States Government to deliver high-quality tuberculosis surveillance, laboratory services, prevention, treatment, and care; (I) a description of activities that serve to coordinate and leverage countries’ domestic resources, including development of plans, procedures, and disease estimates that support effective use of resources from the Global Fund to Fight AIDS, Tuberculosis, and Malaria